Skip to main content

Advertisement

SpringerLink
Log in

Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (p = 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (p = 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mutlu H, Buyukcelik A, Karaca H, Aksahin A, Berk V, Aslan T, Erden A, Akca Z, Ozkan M. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study. Asian Pac J Cancer Prev. 2013;14:3887–9.

    Article  PubMed  Google Scholar 

  2. Seer.cancer.gov/csr/2004_2008/results.

  3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  CAS  PubMed  Google Scholar 

  4. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–9.

    Article  PubMed  Google Scholar 

  5. Mott FE. Mesothelioma: a review. Ochsner J. 2012;12:70–9.

    PubMed Central  PubMed  Google Scholar 

  6. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–704.

    Article  CAS  PubMed  Google Scholar 

  7. Portalone L, Antilli A, Nunziati F, Crispino C, de Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, et al. Associazione Italiana pneumologi ospedalieri thoracic oncology study group. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori. 2005;91:15–8.

    CAS  PubMed  Google Scholar 

  8. Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC, et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer. 2006;53:367–74.

    Article  PubMed  Google Scholar 

  9. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259–63.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28:223.

    Article  CAS  PubMed  Google Scholar 

  12. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30:2509–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  14. Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol. 2013. doi:10.1007/s10147-013-0619-5.

  15. Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P. Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005–2006). Rev Pneumol Clin. 2010;66:255–9.

    Article  CAS  PubMed  Google Scholar 

  16. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–61.

    Article  CAS  PubMed  Google Scholar 

  17. Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am J Clin Oncol. 2011;34:38–42.

    Article  CAS  PubMed  Google Scholar 

  18. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol. 2008;18(3):34.

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Acıbadem Kayseri Hospital, Kayseri, Turkey

    Hasan Mutlu

  2. Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey

    Şeyda Gündüz & Hasan Şenol Coşkun

  3. Department of Medical Oncology, Erciyes University School of Medicine, Kayseri, Turkey

    Halit Karaca

  4. Department of Internal Medicine, Acıbadem University School of Medicine, Istanbul, Turkey

    Abdullah Büyükçelik

  5. Department of Radiation Oncology, Kayseri Training and Research Hospital, Kayseri, Turkey

    Yasemin Benderli Cihan

  6. Department of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey

    Abdülsamet Erden

  7. Department of Radiation Oncology, Mersin Government Hospital, Mersin, Turkey

    Zeki Akca

  8. Tıbbi Onkoloji Bölümü, Tıp Fakültesi, Konyaaltı, Akdeniz Üniversitesi, Antalya, Turkey

    Hasan Mutlu

Authors
  1. Hasan Mutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Şeyda Gündüz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Halit Karaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdullah Büyükçelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasemin Benderli Cihan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdülsamet Erden
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zeki Akca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hasan Şenol Coşkun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasan Mutlu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mutlu, H., Gündüz, Ş., Karaca, H. et al. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. Med Oncol 31, 74 (2014). https://doi.org/10.1007/s12032-014-0074-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0074-9

Keywords

Search

Navigation